Novavax Historical Financial Ratios
| NVAX Stock | USD 7.68 0.19 2.41% |
Novavax is lately reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Invested Capital of 0.0 will help investors to properly organize and evaluate Novavax financial condition quickly.
Novavax |
About Novavax Financial Ratios Analysis
NovavaxFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Novavax investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Novavax financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Novavax history.
Novavax Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Novavax stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novavax sales, a figure that is much harder to manipulate than other Novavax multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Novavax dividend as a percentage of Novavax stock price. Novavax dividend yield is a measure of Novavax stock productivity, which can be interpreted as interest rate earned on an Novavax investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Novavax's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Days Sales Outstanding is fairly stable compared to the past year. Inventory Turnover is likely to rise to 24.33 in 2025, whereas Price To Sales Ratio is likely to drop 1.70 in 2025.
| 2024 | 2025 (projected) | Dividend Yield | 0.007475 | 0.006645 | Price To Sales Ratio | 1.79 | 1.7 |
Novavax fundamentals Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 13.49 | 9.29 | 0.5 | 0.87 | 1.79 | 1.7 | |
| Ptb Ratio | 10.23 | (30.27) | (1.27) | (0.67) | (1.96) | (1.86) | |
| Days Sales Outstanding | 201.08 | 144.88 | 18.8 | 195.0 | 57.94 | 83.58 | |
| Book Value Per Share | 10.9 | (4.73) | (8.11) | (7.11) | (4.1) | (3.89) | |
| Free Cash Flow Yield | (0.0151) | 0.0249 | (0.63) | (1.6) | (0.082) | (0.0861) | |
| Operating Cash Flow Per Share | (0.74) | 4.34 | (5.32) | (7.09) | (0.57) | (0.6) | |
| Stock Based Compensation To Revenue | 0.27 | 0.16 | 0.0815 | 0.15 | 0.0706 | 0.0671 | |
| Capex To Depreciation | 11.18 | 4.54 | 3.2 | 1.43 | 0.27 | 0.26 | |
| Pb Ratio | 10.23 | (30.27) | (1.27) | (0.67) | (1.96) | (1.86) | |
| Ev To Sales | 13.01 | 8.36 | 0.0104 | 0.26 | 1.35 | 1.29 | |
| Free Cash Flow Per Share | (1.69) | 3.57 | (6.51) | (7.67) | (0.66) | (0.69) | |
| Roic | (0.31) | (5.41) | (4.3) | (2.52) | (0.57) | (0.59) | |
| Inventory Turnover | (4.48) | (0.00647) | 24.61 | 8.24 | 23.17 | 24.33 | |
| Net Income Per Share | (7.43) | (23.44) | (8.42) | (5.41) | (1.23) | (1.29) | |
| Days Of Inventory On Hand | (81.44) | (56.4K) | 14.83 | 44.27 | 15.75 | 16.54 | |
| Payables Turnover | 13.75 | 0.0997 | 4.17 | 2.59 | 4.88 | 4.69 | |
| Sales General And Administrative To Revenue | 1.0 | 1.84 | 0.31 | 0.26 | 0.35 | 0.33 | |
| Research And Ddevelopement To Revenue | 1.57 | 2.21 | 0.77 | 1.33 | 0.57 | 0.54 | |
| Capex To Revenue | 0.0995 | 0.11 | 0.0501 | 0.0582 | 0.0191 | 0.0182 | |
| Cash Per Share | 12.35 | 20.36 | 17.1 | 5.64 | 6.07 | 8.7 | |
| Pocfratio | (150.86) | 32.96 | (1.93) | (0.68) | (14.02) | (14.72) | |
| Interest Coverage | (27.52) | (79.83) | (32.43) | (39.3) | 12.4 | 13.02 | |
| Capex To Operating Cash Flow | (0.0136) | (1.28) | 0.18 | (0.22) | (0.0824) | (0.16) | |
| Pfcf Ratio | (66.05) | 40.1 | (1.58) | (0.63) | (12.2) | (12.81) | |
| Days Payables Outstanding | 26.55 | 3.7K | 87.55 | 140.8 | 74.86 | 71.11 | |
| Income Quality | 0.1 | (0.19) | 0.63 | 1.31 | 0.47 | 0.85 | |
| Roe | (0.68) | 4.96 | 1.04 | 0.76 | 0.3 | 0.29 | |
| Ev To Operating Cash Flow | (145.42) | 29.67 | (0.04) | (0.2) | (10.59) | (11.12) | |
| Pe Ratio | (0.74) | (15.01) | (6.1) | (0.89) | (6.53) | (6.85) | |
| Return On Tangible Assets | (0.3) | (0.71) | (0.31) | (0.33) | (0.13) | (0.14) | |
| Ev To Free Cash Flow | (63.67) | 36.1 | (0.0327) | (0.19) | (9.21) | (9.67) | |
| Intangibles To Total Assets | 0.0892 | 0.0529 | 0.0559 | 0.0709 | 0.0689 | 0.0654 | |
| Net Debt To E B I T D A | 0.58 | 0.63 | 1.3 | 0.7 | 1.2 | 1.26 | |
| Current Ratio | 3.88 | 0.9 | 0.69 | 0.7 | 0.98 | 0.93 | |
| Tangible Book Value Per Share | 8.45 | (6.56) | (9.73) | (8.38) | (4.81) | (4.57) | |
| Receivables Turnover | 1.82 | 2.52 | 19.41 | 1.87 | 6.3 | 6.25 | |
| Shareholders Equity Per Share | 10.9 | (4.73) | (8.11) | (7.11) | (4.1) | (3.89) | |
| Debt To Equity | 0.51 | (1.29) | (0.87) | (0.32) | (0.37) | (0.39) | |
| Capex Per Share | 0.95 | 0.77 | 1.19 | 0.58 | 0.0858 | 0.0815 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.